Viking Therapeutics, Inc. (VKTX)
34.87
+0.89
(+2.62%)
USD |
NASDAQ |
Sep 04, 16:00
34.87
0.00 (0.00%)
After-Hours: 20:00
Viking Therapeutics Research and Development Expense (Quarterly) : 115.75M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 115.75M |
| March 31, 2026 | 150.15M |
| December 31, 2025 | 153.46M |
| September 30, 2025 | 89.95M |
| June 30, 2025 | 60.15M |
| March 31, 2025 | 41.39M |
| December 31, 2024 | 30.99M |
| September 30, 2024 | 22.78M |
| June 30, 2024 | 23.77M |
| March 31, 2024 | 24.10M |
| December 31, 2023 | 20.50M |
| September 30, 2023 | 18.38M |
| June 30, 2023 | 13.92M |
| March 31, 2023 | 11.01M |
| December 31, 2022 | 16.18M |
| September 30, 2022 | 11.96M |
| June 30, 2022 | 13.54M |
| March 31, 2022 | 12.56M |
| December 31, 2021 | 9.847M |
| September 30, 2021 | 10.80M |
| June 30, 2021 | 12.80M |
| March 31, 2021 | 11.54M |
| December 31, 2020 | 9.048M |
| September 30, 2020 | 7.116M |
| June 30, 2020 | 7.78M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.987M |
| December 31, 2019 | 6.451M |
| September 30, 2019 | 5.279M |
| June 30, 2019 | 7.333M |
| March 31, 2019 | 4.496M |
| December 31, 2018 | 5.089M |
| September 30, 2018 | 5.687M |
| June 30, 2018 | 5.221M |
| March 31, 2018 | 3.043M |
| December 31, 2017 | 3.033M |
| September 30, 2017 | 3.465M |
| June 30, 2017 | 3.715M |
| March 31, 2017 | 3.528M |
| December 31, 2016 | 2.648M |
| September 30, 2016 | 2.105M |
| June 30, 2016 | 2.371M |
| March 31, 2016 | 1.877M |
| December 31, 2015 | 3.219M |
| September 30, 2015 | 2.508M |
| June 30, 2015 | 1.101M |
| March 31, 2015 | 0.139M |
| June 30, 2014 | 21.24M |
| March 31, 2014 | 0.05M |
| June 30, 2013 | 0.0033M |
| March 31, 2013 | 0.0006M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Eli Lilly & Co. | 3.819B |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Amgen, Inc. | 1.868B |
| Ironwood Pharmaceuticals, Inc. | 21.96M |